Drug
Cdc7 Inhibitor
Cdc7 Inhibitor: highest development phase Phase 1/2, developed by Bristol-Myers Squibb. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Bristol-Myers Squibb
Trials
| Drug | Phase | Indication |
|---|---|---|
| Cdc7-inhibitor (BMS-863233) NCT00838890 | Phase 1/2 | Refractory Hematologic Cancer |
Latest
No recent events.
Follow Cdc7 Inhibitor on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.